Polymorphisms in type I IFN signaling molecules are associated with IFN-induced neutropenia, thrombocytopenia, and neuropsychiatric effects, raising the possibility that patients most likely to well tolerate IFN therapy can be identified. The gene discussed is IFNA1; the disease is Thrombocytopenia.